Product Development Pipeline Status

Product Pipeline

The product portfolio is focused on products for gastro-intestinal conditions targeted at the European, American and Australasian markets. S.L.A. Pharma currently has six products in development for a range of different conditions.
  Phase 1 Phase 2 Phase 3 Submitted Approval

Diltiazem
Anal fissure
   

Metronidazole
Perianal Crohn's disease
   

Eicosapentaenoic acid 99%
Sporadic polyps
   

Familial adenomatous polyposis
   

Naloxone
Constipation
   

Phenylephrine
Faecal incontinence
   

Nicotine
Ulcerative colitis
   
Therapeutic Areas Scientific Articles Product Development Clinical Trials
Business Development Careers Newsroom Contact Links Search

©2009 S.L.A. Pharma AG